Here’s What Strengthened CVS Health (CVS) in Q2

Here’s What Strengthened CVS Health (CVS) in Q2

Wed, September 23, 2026 at 5:25 PM GMT+3 2 min read

• CVS -1.04%

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for "Global Equity Strategy". The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% during the quarter, compared to a 13.90% return for the MSCI World Index, gross dividends reinvested. The Composite remained ahead for the year-to-date period through June 30, 2026, gaining 19.95% versus 9.94% for the benchmark, driven by strong performance from IT holdings, particularly AI-related companies and memory semiconductor suppliers. Please review the Fund's top five holdings to gain insights into its key selections for 2026.

In its second-quarter 2026 investor letter, Polaris Global Equity Strategy highlighted CVS Health Corporation (NYSE:CVS). CVS Health Corporation (NYSE:CVS) provides health solutions in the United States. On September 22, 2026, CVS Health Corporation (NYSE:CVS) closed at $87.10 per share. Over the past month, CVS Health Corporation (NYSE:CVS) declined 8.16% and its shares gained 13.41% over the past 52 weeks. CVS Health Corporation (NYSE:CVS) has a market capitalization of $111.4 billion, with a 52-week trading range between $69.51 and $110.68.

Polaris Global Equity Strategy stated the following regarding CVS Health Corporation (NYSE:CVS) in its Q2 2026 investor letter:

"The Composite markedly outperformed in health care, with five holdings posting double-digit gains. CVS Health Corporation (NYSE:CVS) launched a comprehensive GLP-1 program in June 2026, combining lower-cost access, personalized pharmacist support, and tailored over-the- counter products to manage medication side effects. Investors broadly welcomed the strategy as a way to capture a meaningful share of the surging weight-loss market."

CVS Health Corporation (NYSE:CVS) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 88 hedge fund portfolios held CVS Health Corporation (NYSE:CVS) at the end of the second quarter which was 84 in the previous quarter. While we acknowledge the potential of CVS Health Corporation (NYSE:CVS) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered CVS Health Corporation (NYSE:CVS) and shared why Jim Cramer believes the company's CEO is a "beacon." In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

This article is originally published at Insider Monkey.